Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
PMCID: PMC2701308

No Association between MMP-1 or MMP-3 Polymorphisms and Breast Cancer Susceptibility: A report from the Shanghai Breast Cancer Study


Matrix metalloproteinase (MMP)-1 (interstitial collagenase) and MMP-3 (stromelysin) are structurally related multifunctional enzymes that are involved in physiological and pathological tissue remodeling 1;2. Known to contribute to breast cancer invasion and metastasis 35, roles in breast tumor initiation and progression have also been suggested 610. Expression of these MMPs is often coordinately regulated; the two genes are adjacent on chromosome 11q22.3 and have several similar promoter elements 11;12. Functional polymorphisms resulting from the insertion or deletion of a single nucleotide have been identified in both gene promoters 1315; MMP-1 -1607 1G/2G (rs1799750) and MMP-3 -1612 (also known as -1171) 5A/6A (rs3025058) are in linkage disequilibrium (LD) 16;17. Previous studies have evaluated these single nucleotide polymorphisms (SNPs) in relation to breast cancer risk with both positive 18;19 and null findings 2022, however, other genetic variation in these genes may also contribute to expression differences 11;12;23. This study was therefore undertaken to comprehensively assess individual genetic variation across MMP-1 and MMP-3, and evaluate associations with breast cancer risk among participants of the Shanghai Breast Cancer Study (SBCS).


Study subjects were participants of the SBCS, a large, two-phase, population-based, case-control study of women in urban Shanghai 2426. Briefly, 1,459 (91.1%) cases and 1,556 (90.3%) controls from Phase 1, and 1,989 cases (83.7%) and 1,989 controls (70.4%) from Phase 2 completed in-person interviews. Blood or buccal cell samples were donated by 1,193 cases (81.8%) and 1,310 controls (84.2%) from Phase 1 and 1,932 (97.1%) cases and 1,857 (93.4%) controls from Phase 2. Approval was granted from relevant review boards in both China and the United States; all included subjects gave informed consent.

Haplotype tagging SNPs (htSNPs) were selected from Han Chinese data from the HapMap Project 27 using the Tagger program 28 to capture SNPs with a minimum minor allele frequency (MAF) of 0.05 in either MMP-1 or MMP-3 (± 5kb) with an r2 of 0.90 or greater. Seventeen MMP-1 and seven MMP-3 SNPs were selected; fourteen and six SNPs, respectively, were successfully designed and genotyped in 2006 for 1,062 cases and 1,069 controls from Phase 1, using a Targeted Genotyping System (Affymetrix, Santa Clara, CA) 26.

Two insertion/deletion polymorphisms reported to be functional 1315 were chosen for genotyping using the Sequenom MassARRAY System (Sequenom, Inc., San Diego, CA) for 1,495 cases and 1,437 controls from Phase 2. Blinded duplicate samples and negative controls were included; concordance rates between duplicates were ≥ 99.4%.

To increase the density of genetic markers in this study, data from our recently completed Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix) was included for an additional 11 MMP-1 (± 10kb) and 9 MMP-3 (± 10kb) SNPs for 2,994 participants, including 1,082 cases and 1,085 controls from Phase 1, and 416 cases and 411 controls from Phase 2.

Hardy-Weinberg equilibrium (HWE) was tested by comparing the observed and expected genotype frequencies of the controls (χ2-test). Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were determined by logistic regression analyses using additive models that included adjustment for age, education, and study phase if appropriate. Linkage disequilibrium was assessed by Haploview 29. All statistical tests were two-tailed, and p-values were considered to be statistically significant when ≤ 0.05.


A total of 6,023 women were included in the current study: 2,279 Phase 1 participants and 3,744 Phase 2 participants. Women in both study phases were generally comparable (data not shown). As expected, breast cancer cases were found to differ from controls in regards to known breast cancer risk factors; cases were more likely to have earlier age at menarche, older age at first live birth, a history of breast fibroadenomas, a history of breast cancer among a first degree relative, a higher BMI and/or WHR, and less likely to participate in regular physical activity than controls (data not shown).

SNPs included in the current study are listed in Table 1; their order corresponds to the open reading frames of the genes on the negative strand of chromosome 11. Based on the genotype distribution among controls, three SNPs were found to have MAFs of less than 1% (rs3025079, rs12295590, and rs11600510), and three SNPs were found to deviate from HWE (rs2071231, rs7945189, and rs7127735). Associations with breast cancer were calculated among 1,062 cases and 1,069 controls from Phase 1 for 20 htSNPs, among 1,495 cases and 1,437 controls from Phase 2 for 2 functional SNPs, and among 1,082 cases and 1,085 controls from Phase 1 and 416 cases and 411 controls from Phase 2 for the additional 17 SNPs. None of these 39 SNPs were found to be significantly associated with breast cancer risk in additive models that included adjustment for age, education, and study phase when appropriate. Further, no significant associations were identified under dominant or recessive models (data not shown). The linkage disequilibrium (LD) structure of these 39 polymorphic loci is shown in Figure 1.

Figure 1
LD Structure of MMP-1 and MMP-3 Polymorphisms
Table 1
MMP-1 and MMP-3 SNPs and Breast Cancer Risk, The Shanghai Breast Cancer Study


Known to be involved in cancer invasion and metastasis, MMP-1 and MMP-3 have also been implicated in breast cancer development and progression. MMP-3 expression was found to promote malignant transformation in vitro and the development of spontaneous malignant lesions in mammary glands of mice 68. MMP-1 expression was necessary for breast tumor growth in nude mice 9, and was determined to be positively regulated by Her-2/neu induced Ets-1 in breast cancer cells 10. In humans, both genes were found to be expressed in breast cancer tissues 30. Promoter polymorphisms that influence gene expression have been identified for both MMP-1 and MMP-3 13;15;25. Previous studies on MMP-1-1607 1G/2G (rs1799750) and MMP-3 -1612 (aka -1171) 5A/6A (rs3025058) and breast cancer risk have had mixed results 1822. In the current study, neither the two previously reported functional SNPs, nor other genetic variation in or around MMP-1 or MMP-3, were found to be associated with breast cancer risk. Given the size of our study population, this analysis had greater than 77% power to detect an OR of 1.3 for a SNP with a MAF of 10%, greater than 85% power to detect an OR of 1.25 for a SNP with a MAF of 20%, and greater than 79% power to detect an OR of 1.2 for a SNP with a MAF of 30%. In summary, a total of 42 MMP-1 and MMP-3 polymorphisms were evaluated among a total of 3,016 cases and 3,007 controls in the Shanghai Breast Cancer Study; no associations with breast cancer risk were observed.


This research was supported by USPHS grants R01CA64277, R01CA90899 and R01CA124558. Genotyping assays, using Affymetrix arrays, were conducted at the Vanderbilt Microarray Shared Resource which is supported in part by the Vanderbilt Ingram Cancer Center (P30CA68485).

This research was supported by USPHS grants R01CA64277, R01CA90899 and R01CA124558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. The authors wish to thank the participants and research staff of the Shanghai Breast Cancer Study for their contributions and commitment to this project, and Brandy Venuti for assistance with the preparation of this manuscript. Genotyping assays using Affymetrix arrays were conducted at the Vanderbilt Microarray Shared Resource which is supported in part by the Vanderbilt Ingram Cancer Center (P30CA68485). Sequenom assays were performed by Proactive Genomics (Winstom-Salem, North Carolina).


1. Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252–257. [PMC free article] [PubMed]
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174. [PubMed]
3. Loo WTY, Cheung MNB, Chow LWC. Production of matrix metalloproteinases in specific subpopulations of human-patient breast cancer invading in three dimensional culture system. Life Sciences. 2004;76:743–752. [PubMed]
4. Holliday D, Hughes S, Shaw J, Walker R, Jones JL. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Research. 2007;9:R67. [PMC free article] [PubMed]
5. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat. 2008 [PMC free article] [PubMed]
6. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix Metalloproteinase Stromelysin-1 Triggers a Cascade of Molecular Alterations That Leads to Stable Epithelial-to-Mesenchymal Conversion and a Premalignant Phenotype in Mammary Epithelial Cells. J Cell Biol. 1997;139:1861–1872. [PMC free article] [PubMed]
7. Sternlicht MD, Lochter A, Sympson CJ, et al. The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis. Cell. 1999;98:137–146. [PMC free article] [PubMed]
8. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005;436:123–127. [PMC free article] [PubMed]
9. Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short Hairpin RNA-Mediated Inhibition of Matrix Metalloproteinase-1 in MDA-231 Cells: Effects on Matrix Destruction and Tumor Growth. Cancer Res. 2005;65:11101–11108. [PubMed]
10. Park YH, Jung HH, Ahn JS, Im YH. Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochemical and Biophysical Research Communications. 2008;377:389–394. [PubMed]
11. DiBattista JA, Pelletier JP, Zafarullah M, Fujimoto N, Obata K, Martel-Pelletier J. Coordinate regulation of matrix metalloproteases and tissue inhibitor of metalloproteinase expression in human synovial fibroblasts. J Rheumatol Suppl. 1995;43:123–128. [PubMed]
12. White LA, Maute C, Brinckerhoff CE. ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. Connect Tissue Res. 1997;36:321–335. [PubMed]
13. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215. [PMC free article] [PubMed]
14. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression. J Biol Chem. 1996;271:13055–13060. [PubMed]
15. Rutter JL, Mitchell TI, Buttice G, et al. A Single Nucleotide Polymorphism in the Matrix Metalloproteinase-1 Promoter Creates an Ets Binding Site and Augments Transcription. Cancer Res. 1998;58:5321–5325. [PubMed]
16. Dorr S, Lechtenbohmer N, Rau R, et al. Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther. 2004;6:R199–R207. [PMC free article] [PubMed]
17. Shan K, Ying W, Jian-Hui Z, Wei G, Na W, Yan L. The function of the SNP in the MMP1 and MMP3 promoter in susceptibility to endometriosis in China. Mol Hum Reprod. 2005;11:423–427. [PubMed]
18. Biondi ML, Turri O, Leviti S, et al. MMP1 and MMP3 Polymorphisms in Promoter Regions and Cancer. Clin Chem. 2000;46:2023–2024. [PubMed]
19. Ghilardi G, Biondi ML, Caputo M, et al. A Single Nucleotide Polymorphism in the Matrix Metalloproteinase-3 Promoter Enhances Breast Cancer Susceptibility. Clin Cancer Res. 2002;8:3820–3823. [PubMed]
20. Krippl P, Langsenlehner U, Renner W, et al. The 5A/6A Polymorphism of the Matrix Metalloproteinase 3 Gene Promoter and Breast Cancer. Clin Cancer Res. 2004;10:3518–3520. [PubMed]
21. Przybylowska K, Kluczna A, Zadrozny M, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72. [PubMed]
22. Lei H, Hemminki K, Altieri A, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat. 2007;103:61–69. [PubMed]
23. Benbow U, Rutter JL, Lowrey CH, Brinckerhoff CE. Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter. Br J Cancer. 1998;79:221–228. [PMC free article] [PubMed]
24. Gao YT, Shu XO, Dai Q, et al. Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer. 2000;87:295–300. [PubMed]
25. Ye C, Dai Q, Lu W, et al. Two-stage case-control study of common ATM gene variants in relation to breast cancer risk. Breast Cancer Res Treat. 2007;106:121–126. [PubMed]
26. Beeghly-Fadiel A, Long JR, Gao YT, et al. Common MMP-7 Polymorphisms and Breast Cancer Susceptibility: A Multistage Study of Association and Functionality. Cancer Res. 2008;68:6453–6459. [PMC free article] [PubMed]
27. The International HapMap Project. Nature. 2003;426:789–796. [PubMed]
28. de Bakker PIW, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38:1166–1172. [PMC free article] [PubMed]
29. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265. [PubMed]
30. Haupt LM, Irving RE, Weinstein SR, Irving MG, Griffiths LR. Matrix metalloproteinase localisation by in situ-RT-PCR in archival human breast biopsy material. Molecular and Cellular Probes. 2008;22:83–89. [PubMed]